bERJIS

Berjis is the co-founder of Pointer Bio, which focuses on improving workflows across venture capital and biotechnology startups.

He began studying immunology at an early age while growing up in Kurdistan. At sixteen, he designed a theoretical vaccine framework that led to an invitation to work in the lab of Shiv Pillai at the Ragon Institute of Mass General Brigham, MIT, and Harvard.

He later conducted cancer immunology research at Harvard Medical School with Gordon Freeman, contributing to work on the HHLA-2–KIR3DL3 immune checkpoint pathway.

Berjis is currently wrapping up his Ph.D. in the laboratory of Carl June at the University of Pennsylvania, where his research focuses on next-generation cellular immunotherapies and immuno-oncology approaches.